'Human' insulin versus animal insulin in people with diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2005, Pages

  Richter, Bernd ^a   Neises, Gudrun ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPECIES DIFFERENCE;

ANIMALS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS; SPECIES SPECIFICITY;

EID: 18944401891     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003816.pub2     Document Type: Review

References (118)

1. Altman JJ, Feldman S, Bonnemaire M, Elian N, Squiban P. No increase of hypoglycaemia upon transfer of aged longstanding type 1 diabetic patients to human insulin: a prospective randomized study. The Investigators of the Transfert Study. Diabetes & Metabolism 1998;24(5):419-23.
2. Berger W, Keller U, Honegger B, Jaeggi E. Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus. Lancet 1989;1(8646):1041-44.
3. Beyer J, Enzmann F, Lauerbach M, Althoff P, Bachmann W, Brandstetter K, Cordes U, Dannehl A, Duntsch G, Haas R. Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: first results of a multicenter study. Diabetes Care 1982;5 Suppl 2:140-48.
4. Beyer J, Haas R, Enzmann F, Lauerbach M, Rademacher J, Althoff PH, Bachmann W, Brandstetter K, Cordes U, Dannehl A, Duntsch G, Heun K, Kerp L, Lotz N, Mehnert H, Mitzkat HJ, Petersen K, Rosak C, Sailer D, Schluter K, Schoffling K, Schroder KE, Schumm P. 12 month's therapy with biosynthetic human insulin. Results of a double-blind comparative study with swine and bovine insulin in insulin-dependent diabetics during a multicenter study. Muenchner Medizinische Wochenschrift 1983;Suppl 1:S69-79.
5. Birtwell AJ, Owens DR, Jones IR, Hayes TM, Beale DJ, el Shaboury AH, Arora P, Reeves WG. Comparison of highly purified semi-synthetic insulin and highly purified porcine insulin in the treatment of type I diabetes: interim report of a multi-centre randomised single blind study. Diabetes & Metabolism 1984;10(5):295-8.
6. Clark AJ, Adeniyi-Jones RO, Knight G, Leiper JM, Wiles PG, Jones RH, et al. Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet 1982;2(8294):354-7.
7. Clark AJ, Wiles PG, Leiper JM, Knight G, Adeniyl-Jones RO, Watkins PJ, et al. A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients. Diabetes Care 1982;5(Suppl 2):129-34.
8. Colagiuri S, Miller JJ, Petocz P. Double-blind crossover comparison of human and porcine insulins in patients reporting lack of hypoglycaemia awareness. Lancet 1992;339(8807):1432-5.
9. Davidson JK, Fineberg SE, De Meyts P, Fineberg NS, Galloway JA. Immunological and metabolic responses of patients with history of antibody-induced beef insulin resistance to treatment with beef, pork, human, and sulfated beef insulin. Diabetes Care 1992;15(5):702-4.
10. DeLawter DE, Moss JM. Human insulin: a double-blind clinical study of its effectiveness. Southern Medical Journal 1985;78(6):633-5.
11. Egger M, Smith GD, Teuscher AU, Teuscher A. Influence of human insulin on symptoms and awareness of hypoglycaemia: A randomised double blind crossover trial. BMJ 1991;303(6803):622-6.
12. Fletcher JA, Barnett AH, Pyke DA, Volkmann HP, Hartog M, Perrett AD, et al. Transfer from animal insulins to semisynthetic human insulin: a study in four centres. Diabetes Research 1990;14(4):151-8.
13. Francis AJ, Hanning I, Alberti KG. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. Diabetes Research 1986;3(5):263-8.
14. Gardiner R, Hanna A, Hunt J, Ross S, Tan M. A multicenter open and double-blind study of semi-synthetic human insulin in IDDM patients previously maintained on beef/pork insulin - the Canadian experience. Diabetes 1988;37:138A.
15. George E, Bedford C, Peacey SR, Hardisty CA, Heller SR. Further evidence for a high incidence of nocturnal hypoglycaemia in IDDM: no effect of dose for dose transfer between human and porcine insulins. Diabetic Medicine 1997;14(6):442-8.
16. Gomez-Perez FJ, Rojas H, Chacra AR, Obregon O, Suarez-Russi M, Otero JR, et al. Insulin transference in 198 patients from 6 Latin American countries. Revista de Investigacion Clinica 1995;47(3):173-9.
17. Greene SA, Smith MA, Cartwright B, Baum JD. Comparison of human versus porcine insulin in treatment of diabetes in children. British Medical Journal 1983;287(6405):1578-9.
18. Gunnarsson R, Bolinder J, Ostman J. Transfer from porcine insulin to human insulin in insulin-dependent diabetes mellitus: effects on insulin binding to IgG and glycemic control. Hormone and Metabolic Research 1986;18(1):42-4.
19. Heding LG, Marshall MO, Persson B, Dahlquist G, Thalme B, Lindgren F, et al. Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children. Diabetologia 1984;27(Suppl):96-8.
20. Ho LT, Lam HC, Wu MS, Kwok CF, Jap TS, Tang KT, et al. A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics. Chinese Medical Journal (Taipei) 1991;47(5):313-9.
21. Holman RR, Steemson J, Darling P, Reeves WG, Turner RC. Human ultralente insulin. British Medical Journal 1984;288(6418):665-8.
22. Home PD, Mann NP, Hutchison AS, Park R, Walford S, Murphy M, et al. A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabetic Medicine 1984;1(2):93-8.
23. Iavicoli M, Di Mario U, Coronel GA, Musacchio N, Arduini P. Insulin antibodies and immune complexes in long-term diabetics switched to monocomponent human insulin. Minerva Endocrinologica 1984;9(2):115-20.
24. Jovanovic-Peterson L, Kitzmiller JL, Peterson CM. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. American Journal of Obstetrics and Gynecology 1992;167(5):1325-30.
25. Karam J, Brink S, Clements R, Miller L, Raskin P. Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: a double-blind, multicenter clinical trial. Diabetes Care 1983;6(Suppl 1):56-60.
26. Lam HC, Tang KT, Wang JT, Liu YF, Wang LM, Ho LT. Immunogenicity of monocomponent human and porcine insulin in non-insulin dependent diabetes mellitus. Chinese Medical Journal (Taipei) 1988;41(3):217-22.
27. Lam HC, Ho LT, Tang KT, Wang LM, Kwok CF, Liu YF, et al. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. Journal of Formosan Medical Association 1989;88(4):346-51.
28. Larkins RG, Zajac J, Saunders R, Read A, Hopper JL. Comparative double-blind trial of the effectiveness and antigenicity of semisynthetic human insulin and purified porcine insulin in newly treated diabetic subjects. Australian and New Zealand Journal of Medicine 1986;16(2):206-10.
29. Larsen ML, Bjerrum P, Egstrup K. A comparison of semisynthetic human insulin and porcine insulin in the treatment of established diabetes. Danish Medical Bulletin 1984;31(3):243-4.
30. MacLeod KM, Gold AE, Frier BM. Frequency, severity and symptomatology of hypoglycaemia: a comparative trial of human and porcine insulins in type 1 diabetic patients. Diabetic Medicine 1995;12(2):134-41.
31. Mann NP, Johnston DI, Reeves WG, Murphy MA. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. British Medical Journal 1983;287(6405):1580-2.
32. Maran A, Lomas J, Archibald H, MacDonald IA, Gale EA, Amiel SA. Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin. BMJ 1993;306(6871):167-71.
33. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Research 1988;9(4):169-75.
34. Matyka KA, Maran A, Cranston I, et al. Human insulin does not induce de novo changes in the clinical presentation of hypoglycaemia in Type 1 diabetes mellitus. Diabetic Medicine 1995;12:S25-6.
35. Moffitt PS, Colagiuri S, Miller JJ, Hall CA. Human (semisynthetic) insulin and porcine insulin in the treatment of non-insulin-dependent diabetes. A double-blind, comparative clinical trial. Medical Journal of Australia 1984;140(4):200-2.
36. Oswald GA, Yudkin JS. A within patient cross over trial of 4 insulin regimens in antibody-negative, C-peptide negative patients. Diabetes Research 1987;4(2):85-9.
37. Pedersen C, Hoegholm A. A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Diabetic Medicine 1987;4(4):304-6.
38. Porta M, Pigino M, Minonne A, Gamba S, Barolo P, Sivieri R, et al. A multicentre controlled study of the possible effects of semisynthetic human insulin on the plasma levels of factor VIII-related antigen. Giornale Italiano di Diabetologia 1988;8(3):249-52.
39. Rogala H, Czyzyk A, Lawecki J. Immunogenicity of semisynthetic human insulin Novo--five year prospective studies. Polskie Archivum Medycyny Wewnetrznej 1993;89(6):492-8.
40. Russo EM, Wajchenberg BL, Romaldini JH, Liberman B, Gross JL, Reis LC. Comparative multicenter study of bovine insulin with forms more purified of swine and human insulin in the treatment of type 1 diabetes mellitus. Revista da Associacao Medica Brasileira 1991;37(2):73-8.
41. Sailer D, Volkholz HJ, Kolb S, Pichl J. Comparison of a semisynthetic human insulin and swine insulin. Fortschritte der Medizin 1986;104(16):340-2.
42. Santana PF, Mateo-de-Acosta FO, Lopez AC, Robaina R. A clinical trial controlled with single component swine insulin and semisynthetic human insulin. Influence of antibody titers. Revista Cubana de Medicina 1987;26(7):713-20.
43. Selam JL, Turner D, Woertz L, Eichner HL, Lauritano A, Charles MA. Comparison of the safety and effectiveness of human and bovine long-acting insulins. Diabetes Research 1989;12(3):131-4.
44. Storms GE, Lutterman JA, van 't LA. Efficacy and immunogenicity of human and monocomponent porcine insulin: a randomized double-blind study in diabetic patients previously treated with insulin. Netherlands Journal of Medicine 1986;29(10):296-302.
45. Tindall H, Bodansky HJ, Stickland M, Wales JK. A strategy for selection of elderly type 2 diabetic patients for insulin therapy, and a comparison of two insulin preparations. Diabetic Medicine 1988;5(6):533-6.
46. Altman JJ, Elian N, Bonnemaire M, Calmar S, Feldman S. Safety of human insulin in poor-sighted elderly diabetic patients. Diabetes Care 1999;22(12):2089.
47. Bannai C, Kawai K, Murayama Y, Yamashita K. Comparison of the absorption and biological activity of NPH human insulin (recombinant DNA) and NPH porcine insulin injected subcutaneously in type II diabetic patients. Hormone and Metabolic Research 1986;18(11):784-5.
48. Barbera R, Lanza G, Cattaneo G, Fontana S. Comparison of 12-month treatment with porcine and human insulin (semisynthetic and biosynthetic). Minerva Medica 1986;77(36):1621-4.
49. Brooks AP, Hasager BA. Safe changeover to Human Protaphane from porcine Semitard MC insulin. Practical Diabetes 1989;6(2):74-5.
50. Castillo M, Nemery A, Verdin E, Lefebvre PJ, Luyckx AS. Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations. European Journal of Clinical Pharmacology 1983;25(6):767-71.
51. Chandraprasert S, Bunnag SC. Insulin antibodies in diabetics after changeover from conventional NPH to highly purified insulin. Annals of the Academy of Medicine, Singapore 1985;14(2):289-93.
52. Charles MA, Szekeres A, Staten M, Worcester B, Walsh KM. Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes. Diabetes Care 1983;6(Suppl 1):29-34.
53. Davidson JK. Transferring patients with insulin-dependent diabetes mellitus from animal-source insulins to recombinant DNA human insulin: Clinical experience. Clinical Therapeutics 1989;11(3):319-30.
54. Dorchy H, Duchateau J, D'Hooge D. Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin. Diabetes & Metabolism 1988;14(4):415-21.
55. Dorchy H, Duchateau J, Bosson D, D'Hooge D. Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two-year follow-up. Diabetes & Metabolism 1989;15(3):107-10.
56. Etti H, Bamberg E, Enzmann F, Haupt E. Biosynthetic human insulin in comparison with conventional intermediary insulin from cattle. Medizinische Welt 1983;34(37):1007-9.
57. Etti H, Haupt E. Biosynthetic human insulin. Comparison of the activity profile of human NPH-insulin and swine NPH-insulin in type I diabetics. Muenchner Medizinische Wochenschrift 1983;Suppl 1:S53-6.
58. Fankhauser S, von Rohr E. Are there problems in changing diabetic patients from animal to human insulin?. Therapeutische Umschau 1990;47(1):41-8.
59. Fenichel P, Viard R, Harter M, Issa-Sayegh M, Brucker F, Strulo S, et al. Remission of diabetes mellitus treated from the beginning with intensive insulin. Comparative effects of porcine and human insulin. Presse Medicale 1983;12(44):2822-3.
60. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ. Immunologic improvement resulting from the transfer of animal insulin-treated diabetic subjects to human insulin (recombinant DNA). Diabetes Care 1982;5(Suppl 2):107-13.
61. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983;25(6):465-9.
62. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care 1982;5(Suppl 2):119-25.
63. Gadia M, Sosenko JM, Salzman R, Lauritano AA, Haycock P. NPH human insulin: does it work in a once-a-day regimen?. Clinical Therapeutics 1989;11(1):120-8.
64. Galloway JA, Peck FB, Jr, Fineberg SE, Spradlin CT, Marsden JH, Allemenos D, et al. The U.S. "new patient" and "transfer" studies. Diabetes Care 1982;5(Suppl 2):135-9.
65. Garber AJ, Davidson JA, Krosnick A, Beaser RS, Anderson JH, Jr. Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. Clinical Therapeutics 1991;13(5):627-36.
66. Haupt E, Hoppe FU, Rudolf R, Bamberg E. Treatment of type II diabetes using homologous intermediate-acting insulin combinations. Comparison of the effectiveness of 5 commonly used preparations. Deutsche Medizinische Wochenschrift 1987;112(31-32):1209-12.
67. Kabadi UM, Birkenholz M. Metabolic control following transfer from mixed bovine-porcine insulin to human insulin in subjects with IDDM: influence of the presence of insulin antibodies. Diabetes Research 1992;19(4):187-93.
68. Kahn CB, Lamberton RP, Krauss DS. Transfer from animal to human insulin: a clinical experience. Rhode Island Medicine 1992;75(6):313-5.
69. Krawczuk RM, Pomaski J, Peczynska J, Urban M. Clinical experience in treatment of diabetic children with pork and humanized insulins in the first months of the disease. Pediatria Polska 1993;68(12):43-8.
70. Kuhnau J, Rudiger H, Goetz K. Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins. Report of a prospective study with 40 cases. Experimental and Clinical Endocrinology 1984;83(2):161-7.
71. Lacigova S, Perusicova J, Dohnalova L, Mertl J. Clinical experience with changing type I diabetes patients from animal to human insulin administered by the NovoPen 3 applicator. Vnitrni Lekarstvi 1997;43(3):137-41.
72. Laron Z, Feinmesser P, Albag Y, Ofan R, Karp M. Hypoglycaemia in newly diagnosed diabetic children and adolescents- comparison between human and porcine insulin. Diabetologia 1988;31(7):454.
73. Lauritano AA, Clements RS, Jr, Bell D. Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin. Clinical Therapeutics 1989;11(2):268-77.
74. Le Floch JP, Attali JR, Cathelineau G, Lubetzki L, Perlemuter L, Senan C. Changes in the level of anti-insulin antibodies and circulating immune complexes in diabetics treated with human insulin or monocomposed porcine insulin for a year. A multicenter study. Presse Medicale 1987;16(35):1744-7.
75. Leiper JM, Lowe GD, Anderson J, Burns P, Cohen HN, Manderson WG, et al. Effects of diabetic control and biosynthetic human insulin on blood rheology in established diabetics. Diabetes Research 1984;1(1):27-30.
76. Leiper JM, Paterson KR, Lunan CB, MacCuish AC. A comparison of biosynthetic human insulin with porcine insulin in the blood glucose control of diabetic pregnancy. Diabetic Medicine 1986;3(1):49-51.
77. Leiper JM, Campbell RR, Curtis LD, Fisher BM, Hunter KR, Knight G, et al. Glycaemic control in diabetic patients transferred from therapy with animal insulins to human crystalline zinc insulin of recombinant DNA origin: a multicentre study. Diabetes Research 1987;4(1):1-4.
78. Luyckx AS, Daubresse JC, Jaminet C, Scheen A, Lefebvre PJ. Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin. Acta Diabetologia Latina 1986;23(2):101-6.
79. Miglani S, Goswami R, Tandon N, Dudha A, Kochupillai N. Glycaemic control and microvascular complication among patients with youth onset diabetes in India using differing types of insulin and methods of glucose monitoring. Diabetes Research and Clinical Practice 2004;65:183-5.
80. Nazim A, Sieradzki J, Szurkowska M, Pach D, Kostecka-Matyja M. Dynamics of the changes in insulin requirement during the treatment with biosynthetic human insulin. Wiadomosci Lekarskie 1992;45(7-8):259-62.
81. Peacock I, Tattersall RB, Taylor A, Douglas CA, Reeves WG. Effects of new insulins on insulin and C-peptide antibodies, insulin dose, and diabetic control. Lancet 1983;1(8317):149-52.
82. Petunina NA, Balabolkin MI, Mkrtumian AM, Sergeev AV, Nedosugova LV. The use of highly purified Iletin-II-type porcine insulins and human insulin preparations in clinical practice. Terapevticheskii Arkhiv 1993;65(10):29-31.
83. Raskin P, Etzwiler DD, Davidson JK, Nolte M, Stephens JW, MacGillivray M, et al. Rapid decrease of insulin-specific IgG antibody levels in insulin-dependent patients transferred to semi-synthetic human insulin. Diabetes Research 1987;6(3):123-8.
84. Renner R, Vocke K, Hepp KD. Comparison of the effects of protamine-bound NPH porcine insulin and NPH human insulin in type 1 and 2 diabetes. Deutsche Medizinische Wochenschrift 1986;111(35):1316-20.
85. Sacchetti C, Foco A, David O, Balboni R, Gargano P, Cerutti F, et al. Use of semisynthetic human insulin in juvenile insulin-dependent diabetes mellitus. Minerva Pediatrica 1989;41(5):221-2.
86. Sachse G, Maser E, Federlin K. Long-term therapy with human insulin. Clinical experiences. Deutsche Medizinische Wochenschrift 1985;110(11):403-6.
87. Saner B, Fankhauser S. Ultratard HM, a new human insulin. Advantages as compared to current preparations?. Schweizerische Medizinische Wochenschrift 1986;116(4):116-9.
88. Struwe FE. Human insulin and bovine insulin compared. Initial clinical results of treating diabetic children with biosynthetic human insulin. Muenchner Medizinische Wochenschrift 1983;Suppl 1:S112-15.
89. Vanelli M, Bolondi O, Boselli E, Chiari G, Vittorangeli R, Rasori E, et al. Short-term follow-up of human insulin (recombinant DNA) treatment of diabetic children pretreated with insulin of animal origin. Minerva Pediatrica 1987;39(15-16):669-74.
90. Venekamp WJ, van der Hooft JC, Jacobsen L, van Schaik CL. Immunogenicity of bovine, porcine and semisynthetic human insulin. Netherlands Journal of Medicine 1985;28(Suppl 1):57-8.
91. Vidal J, Manzanares JM, Rodriguez C, Coves MJ, Guijo J, Gomis R, et al. Efficiency of NPH insulin in two doses, compared to a monodose of insulin in the treatment of type II diabetes mellitus. Endocrinologia 1994;41(2):45-7.
92. Yue DK, Turtle JR. Antigenicity of "monocomponent" pork insulin in diabetic subjects. Diabetes 1975;24(7):625-32.
93. Airey CM, William DR, Martin PG, Bennett CM, Spoor PA. Hypoglycaemia induced by exogeneous insulin - 'human' and animal insulin compared. Diabetic Medicine 2000;17:416-32.
94. Armitage M, Brooks A, Betts P, Wilkin TJ, McCaughey E, Cove D, et al. Insulin resistance and insulin antibodies: Fact or hallowed fiction?. Practical Diabetes 1988;5(5):200-2.
95. Berger M. Human insulin: Much ado about hypoglycaemia (un)awareness. Diabetologia 1987;30(11):829-83.
96. Berger W, Keller U, Honegger B, Jaeggi E. Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus. Lancet 1989;1(8646):1041-4.
97. Bragd J, Adamson U, Lins PE, Wredling R, Oskarsson P. A repeated cross-sectional survey of severe hypoglycaemia in 178 type 1 diabetes mellitus patients performed in 1984 and 1998. Diabetic Medicine 2003;20:216-9.
98. Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987;34(3):350-71.
99. Chien YW. Human insulin: Basic sciences to therapeutic uses. Drug Development and Industrial Pharmacy 1996;22(8):753-89.
100. Cryer PE. Hypoglycemia unawareness in IDDM. Diabetes Care 1993;16(3 Suppl. 3):40-7.
101. Egger M, Davey SG, Teuscher A. Human insulin and unawareness of hypoglycaemia: Need for a large randomised trial. British Medical Journal 1992;305(6849):351-5.
102. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
103. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
104. Everett J, Kerr D. Changing from porcine to human insulin. Drugs 1994;47(2):286-96.
105. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd Edition. New York: Wiley, 1981:217-34.
106. Gregory R, Tattersall RB. Bovine and human NPH insulins as T cell immunogens. Diabetes Research and Clinical Practice 1993;20(2):139-46.
107. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993;16(3 Suppl. 3):90-100.
108. Hirst J. Adverse effects of human insulin. Lancet 1998;352(9141):1710.
109. Hirst J. 'Human' and animal insulin compared--a thorough comparison?. Diabetic Medicine 2001;18(2):165-6.
110. Jadad AR MRCDeal. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
111. Patrick AW, Williams G. Adverse effects of exogenous insulin. Clinical features, management and prevention. Drug Safety 1993;8(6):427-44.
112. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16(3 Suppl. 3):155-65.
113. Schulz KF Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
114. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54:1045-55.
115. Teuscher A, Berger WG. Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;2(8555):382-5.
116. Teuscher A. Human insulin 1992: A significant independent risk factor for sudden hypoglycaemia?. Practical Diabetes 1992;9(5):174-6.
117. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 1989;12(9):641-8.
118. Richter B, Neises G, Bergerhoff K. Human versus animal insulin in people with diabetes mellitus - a systematic review. Endocrinology and Metabolism Clinics - Clinics of North America 2002;31(3):723-49.